Michael L Alosco1,2, Michael A Sugarman1,3, Lilah M Besser4, Yorghos Tripodis1,5, Brett Martin1,6, Joseph N Palmisano1,6, Neil W Kowall1,2,7,8, Rhoda Au2,9,10,11, Jesse Mez1,2, Charles DeCarli12, Thor D Stein1,7,13,14, Ann C McKee1,2,7,13,14, Ronald J Killiany1,11,15, Robert A Stern1,2,11,16. 1. Boston University Alzheimer's Disease Center, Boston University School of Medicine, Boston, MA, USA. 2. Department of Neurology, Boston University School of Medicine, Boston, MA, USA. 3. Department of Neuropsychology, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, USA. 4. National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, USA. 5. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. 6. Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA, USA. 7. Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA. 8. Neurology Service, VA Boston Healthcare System, Boston, MA, USA. 9. Framingham Heart Study, National Heart, Lung, and Blood Institute, Framingham, MA, USA. 10. Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA. 11. Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA, USA. 12. Department of Neurology, University of California at Davis Health System, Sacramento, CA, USA. 13. U.S. Department of Veteran Affairs, VA Boston Healthcare System, Boston, MA, USA. 14. Department of Veterans Affairs Medical Center, Bedford, MA, USA. 15. Center for Biomedical Imaging, Boston University School of Medicine, Boston, MA, USA. 16. Department of Neurosurgery, Boston University School of Medicine, Boston, MA, USA.
Abstract
BACKGROUND: White matter hyperintensities (WMH) on magnetic resonance imaging (MRI) have been postulated to be a core feature of Alzheimer's disease. Clinicopathological studies are needed to elucidate and confirm this possibility. OBJECTIVE: This study examined: 1) the association between antemortem WMH and autopsy-confirmed Alzheimer's disease neuropathology (ADNP), 2) the relationship between WMH and dementia in participants with ADNP, and 3) the relationships among cerebrovascular disease, WMH, and ADNP. METHODS: The sample included 82 participants from the National Alzheimer's Coordinating Center's Data Sets who had quantitated volume of WMH from antemortem FLAIR MRI and available neuropathological data. The Clinical Dementia Rating (CDR) scale (from MRI visit) operationalized dementia status. ADNP+ was defined by moderate to frequent neuritic plaques and Braak stage III-VI at autopsy. Cerebrovascular disease neuropathology included infarcts or lacunes, microinfarcts, arteriolosclerosis, atherosclerosis, and cerebral amyloid angiopathy. RESULTS: 60/82 participants were ADNP+. Greater volume of WMH predicted increased odds for ADNP (p = 0.037). In ADNP+ participants, greater WMH corresponded with increased odds for dementia (CDR≥1; p = 0.038). WMH predicted cerebral amyloid angiopathy, microinfarcts, infarcts, and lacunes (ps < 0.04). ADNP+ participants were more likely to have moderate-severe arteriolosclerosis and cerebral amyloid angiopathy compared to ADNP-participants (ps < 0.04). CONCLUSIONS: This study found a direct association between total volume of WMH and increased odds for having ADNP. In patients with Alzheimer's disease, FLAIR MRI WMH may be able to provide key insight into disease severity and progression. The association between WMH and ADNP may be explained by underlying cerebrovascular disease.
BACKGROUND:White matter hyperintensities (WMH) on magnetic resonance imaging (MRI) have been postulated to be a core feature of Alzheimer's disease. Clinicopathological studies are needed to elucidate and confirm this possibility. OBJECTIVE: This study examined: 1) the association between antemortem WMH and autopsy-confirmed Alzheimer's disease neuropathology (ADNP), 2) the relationship between WMH and dementia in participants with ADNP, and 3) the relationships among cerebrovascular disease, WMH, and ADNP. METHODS: The sample included 82 participants from the National Alzheimer's Coordinating Center's Data Sets who had quantitated volume of WMH from antemortem FLAIR MRI and available neuropathological data. The Clinical Dementia Rating (CDR) scale (from MRI visit) operationalized dementia status. ADNP+ was defined by moderate to frequent neuritic plaques and Braak stage III-VI at autopsy. Cerebrovascular disease neuropathology included infarcts or lacunes, microinfarcts, arteriolosclerosis, atherosclerosis, and cerebral amyloid angiopathy. RESULTS: 60/82 participants were ADNP+. Greater volume of WMH predicted increased odds for ADNP (p = 0.037). In ADNP+participants, greater WMH corresponded with increased odds for dementia (CDR≥1; p = 0.038). WMH predicted cerebral amyloid angiopathy, microinfarcts, infarcts, and lacunes (ps < 0.04). ADNP+participants were more likely to have moderate-severe arteriolosclerosis and cerebral amyloid angiopathy compared to ADNP-participants (ps < 0.04). CONCLUSIONS: This study found a direct association between total volume of WMH and increased odds for having ADNP. In patients with Alzheimer's disease, FLAIR MRI WMH may be able to provide key insight into disease severity and progression. The association between WMH and ADNP may be explained by underlying cerebrovascular disease.
Entities:
Keywords:
Alzheimer’s disease; Alzheimer’s disease neuropathology; cerebrovascular zzm321990disease; dementia; magnetic resonance imaging; white matter hyperintensities
Authors: J C Rajapakse; J N Giedd; C DeCarli; J W Snell; A McLaughlin; Y C Vauss; A L Krain; S Hamburger; J L Rapoport Journal: Magn Reson Imaging Date: 1996 Impact factor: 2.546
Authors: Timo Grimmer; Maximilian Faust; Florian Auer; Panagiotis Alexopoulos; Hans Förstl; Gjermund Henriksen; Robert Perneczky; Christian Sorg; Behrooz H Yousefi; Alexander Drzezga; Alexander Kurz Journal: Neurobiol Aging Date: 2012-03-10 Impact factor: 4.673
Authors: Ju-Hee Kang; Magdalena Korecka; Michal J Figurski; Jon B Toledo; Kaj Blennow; Henrik Zetterberg; Teresa Waligorska; Magdalena Brylska; Leona Fields; Nirali Shah; Holly Soares; Robert A Dean; Hugo Vanderstichele; Ronald C Petersen; Paul S Aisen; Andrew J Saykin; Michael W Weiner; John Q Trojanowski; Leslie M Shaw Journal: Alzheimers Dement Date: 2015-07 Impact factor: 21.566
Authors: M O'Sullivan; D J Lythgoe; A C Pereira; P E Summers; J M Jarosz; S C R Williams; H S Markus Journal: Neurology Date: 2002-08-13 Impact factor: 9.910
Authors: Michel Bilello; Jimit Doshi; S Ali Nabavizadeh; Jon B Toledo; Guray Erus; Sharon X Xie; John Q Trojanowski; Xiaoyan Han; Christos Davatzikos Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Josephine Barnes; Owen T Carmichael; Kelvin K Leung; Christopher Schwarz; Gerard R Ridgway; Jonathan W Bartlett; Ian B Malone; Jonathan M Schott; Martin N Rossor; Geert Jan Biessels; Charlie DeCarli; Nick C Fox Journal: Neurobiol Aging Date: 2013-03-21 Impact factor: 4.673
Authors: Isabelle Pelcher; Christian Puzo; Yorghos Tripodis; Hugo J Aparicio; Eric G Steinberg; Alyssa Phelps; Brett Martin; Joseph N Palmisano; Elizabeth Vassey; Cutter Lindbergh; Ann C McKee; Thor D Stein; Ronald J Killiany; Rhoda Au; Neil W Kowall; Robert A Stern; Jesse Mez; Michael L Alosco Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Konstantinos Arfanakis; Arnold M Evia; Sue E Leurgans; Luis F C Cardoso; Arman Kulkarni; Nabil Alqam; Lucas F Lopes; Diego Vieira; David A Bennett; Julie A Schneider Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Madeline Uretsky; Sylvain Bouix; Ronald J Killiany; Yorghos Tripodis; Brett Martin; Joseph Palmisano; Asim Z Mian; Karen Buch; Chad Farris; Daniel H Daneshvar; Brigid Dwyer; Lee Goldstein; Douglas Katz; Christopher Nowinski; Robert Cantu; Neil Kowall; Bertrand Russell Huber; Robert A Stern; Victor E Alvarez; Thor D Stein; Ann McKee; Jesse Mez; Michael L Alosco Journal: Neurology Date: 2021-11-24 Impact factor: 9.910
Authors: Simon Zhornitsky; Shefali Chaudhary; Thang M Le; Yu Chen; Sheng Zhang; Stéphane Potvin; Herta H Chao; Christopher H van Dyck; Chiang-Shan R Li Journal: Psychiatry Res Neuroimaging Date: 2021-08-29 Impact factor: 2.376
Authors: Zhiyu Cao; Yingren Mai; Wenli Fang; Ming Lei; Yishan Luo; Lei Zhao; Wang Liao; Qun Yu; Jiaxin Xu; Yuting Ruan; Songhua Xiao; Vincent C T Mok; Lin Shi; Jun Liu Journal: Front Hum Neurosci Date: 2022-06-14 Impact factor: 3.473
Authors: Michael A Sugarman; Henrik Zetterberg; Kaj Blennow; Yorghos Tripodis; Ann C McKee; Thor D Stein; Brett Martin; Joseph N Palmisano; Eric G Steinberg; Irene Simkin; Andrew E Budson; Ronald Killiany; Maureen K O'Connor; Rhoda Au; Wendy Wei Qiao Qiu; Lee E Goldstein; Neil W Kowall; Jesse Mez; Robert A Stern; Michael L Alosco Journal: Neurobiol Aging Date: 2020-05-29 Impact factor: 4.673
Authors: Lester Y Leung; Sunyang Fu; Patrick H Luetmer; David F Kallmes; Neel Madan; Gene Weinstein; Vance T Lehman; Charlotte H Rydberg; Jason Nelson; Hongfang Liu; David M Kent Journal: BMC Neurol Date: 2021-05-11 Impact factor: 2.474
Authors: Namhee Kim; Konstantinos Arfanakis; Sue E Leurgans; Jingyun Yang; Debra A Fleischman; S Duke Han; Neelum T Aggarwal; Melissa Lamar; Lei Yu; Victoria N Poole; David A Bennett; Lisa L Barnes Journal: J Neurosci Methods Date: 2021-05-27 Impact factor: 2.987
Authors: Philippe Desmarais; Andrew F Gao; Julia Keith; Mario Masellis; Krista Lanctôt; Ekaterina Rogaeva; Joel Ramirez; Nathan Herrmann; Donald T Stuss; Sandra E Black Journal: Alzheimers Res Ther Date: 2021-07-13 Impact factor: 6.982